Orum Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Orum Therapeutics is a biotech company listed on KOSDAQ, Korea's tech-focused stock exchange, that develops experimental cancer medicines designed to destroy disease-causing proteins inside specific cells.
Its core platform, which it calls DAC (Degrader-Antibody Conjugate), combines two established drug-design approaches: the precise cell-targeting ability of antibody-drug conjugates and the protein-destroying mechanism of targeted protein degradation. The company's pipeline is built entirely around this proprietary dual-precision technology, which it applies across multiple disease areas.
Summary is AI-generated and may contain errors · figures from DART filings
Orum Therapeutics in five facts
What does Orum Therapeutics do?
Orum Therapeutics is a biotech company listed on KOSDAQ, Korea's tech-focused stock exchange, that develops experimental cancer medicines designed to destroy disease-causing proteins inside specific cells.
Where is Orum Therapeutics listed and in which sector?
Orum Therapeutics (Korean name: 오름테라퓨틱) trades under KRX code 475830 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Orum Therapeutics?
Its market capitalisation was US$282.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Orum Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, Orum Therapeutics reported revenue of US$17.8K, an operating loss of US$39.1M and a net loss of US$31.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 99.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 21
- Notice of general shareholders' meetingOct 8
- DisclosureSep 17
- Shareholder register closure / record date setSep 10
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 10
- Investor relations (IR) meetingAug 31
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Orum Therapeutics reported consolidated results for FY2025: revenue of US$16.1K (−99.89% year on year), an operating loss of US$35.4M and a net loss of US$28.7M.
Earnings · Mar 5 - [Amended] Material event report (rights offering)Capital raise · Jan 8
- [Attachment amended] Material event report (rights offering)Capital raise · Jan 8